Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite
Information source: Research Center Borstel
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Asthma
Intervention: ramatroban (Drug); montelukast (Drug)
Phase: Phase 2/Phase 3
Status: Recruiting
Sponsored by: Research Center Borstel Official(s) and/or principal investigator(s):
Peter Zabel, Prof., Principal Investigator, Affiliation: Research Center Borstel
Overall contact:
Jürgen Welling, MD, Phone: 0049-(0)4537-188-, Email: jwelling@fz-borstel.de
Summary
The purpose of this study is to examine wether the combination of Ramatroban/Montelukast is
as effective as Montelukast alone in patients with mild to moderate atopic asthma (GINA I
and II) sensitive to house dust mite. The test is performed by a specific inhalative
provocation.
Clinical Details
Official title: A Randomized Double-Blind and Placebo-Controlled Study to the Influence of Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Patients With Mild to Moderate Atopic Asthma (House Dust Mite)
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Primary outcome: Lung function by spirometryAllergen concentration for specific bronchoprovocation
Secondary outcome: Blood level of thromboxane and leukotriene metabolite
Detailed description:
In the early allergic response in asthma, allergens connect to IgE on mast cells and
basophile granulocytes. For that there are 3 main pathways in activation:
Besides quick liberation of Histamine and induction of cytokines there is a liberation of
mediators from the arachidonate metabolism. In addition to Histamine there are especially
Prostaglandin PGD2, Leukotriene LTC4 and also Thromboxane A2 for the classic symptoms of the
early allergic reaction responsible. All of those mediators have potent bronchoconstrictive
activity.
Prostaglandin D2 and Thromboxane A2 work on Thromboxane receptors. LTC4 links to
Cys-LT-receptors.
According to an in-vitro-model of the early allergic reaction in human precision-cut lung
slices with passive specific sensitization against grass-pollen, it has been shown that the
early allergic response can only be suppressed partly by giving Antihistamines, Leukotriene
receptor antagonists or Thromboxane receptor antagonist all on its own. It goes in consent
with clinical findings, that all of these drugs alone have just an insufficient activity on
asthma.
In the described human in-vitro-model the combination of Thromboxane receptor antagonist
with Leukotriene receptor antagonist (Montelukast) blocked the early response in asthma
completely.
These findings are the rationale for our study because so far there is no clinical data
about the effect of the combination of Leukotriene receptor antagonist (Montelukast) with
Thromboxane receptor antagonist.
The drug Montelukast is a Leukotriene receptor antagonist which is known for the treatment
of mild to moderate asthma in Germany. According to the GINA-Guidelines Montelukast is given
in addition to steroids and β-mimetics in asthma severity grade II and III.
The drug Ramatroban is a Thromboxane A2 receptor antagonist which is in Japan allowed for
the treatment of allergic rhinitis. It also has an anti-asthmatic effect because it blocks
bronchoconstriction, hyperresponsiveness of the airways and infiltration of inflammation
cells. Furthermore, it has positive effects on allergic rhinitis by blocking the
permeability of capillaries, blocking the nasal hyperresponsiveness and the infiltration of
the mucosa by eosinophils.
During the studies Ramatroban has proved to be a save drug for the indication allergic
rhinitis and also allergic asthma. In contrast to sufficient effectiveness in the indication
allergic rhinitis it has been said that there is just insufficient effectiveness in the
indication asthma.
About the combination of Ramatroban and Montelukast exists no clinical data so the study at
hand examines the effect of Ramatroban/Montelukast versus Montelukast/Placebo on the early
allergic reaction in patients with mild to moderate atopic asthma (GINA I and II) sensitive
to house dust mites in a specific inhalative provocation.
Eligibility
Minimum age: 18 Years.
Maximum age: 65 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Atopic (house dust mite) asthma
- Severity GINA one and two
Exclusion Criteria:
- No reaction in specific bronchial provocation test
- Other kind of clinical relevant atopic reaction
Locations and Contacts
Jürgen Welling, MD, Phone: 0049-(0)4537-188-, Email: jwelling@fz-borstel.de
Research Center Borstel, Borstel 23845, Germany; Recruiting
Jürgen Welling, MD, Phone: 0049-(0)4537-188-, Email: jwelling@fz-borstel.de
Frank Eberhardt, MD, Phone: 0049-(0)4537-188-, Email: feber@fz-borstel.de
Jürgen Welling, MD, Sub-Investigator
Additional Information
Related publications: Wohlsen A, Martin C, Vollmer E, Branscheid D, Magnussen H, Becker WM, Lepp U, Uhlig S. The early allergic response in small airways of human precision-cut lung slices. Eur Respir J. 2003 Jun;21(6):1024-32.
Starting date: April 2005
Ending date: April 2007
Last updated: May 18, 2006
|
